Swedish-Nature-09-1248x672

iLite CDC Bioassays

Accurate Assessment of Antibody-Mediated Complement-Dependent Cytotoxicity

Assay-development-504x672

Accurate Assessment of Antibody-Mediated CDC

CDC Bioassays

Based on Svar’s proprietary iLite® technology, our Complement-Dependent Cytotoxicity (CDC) Bioassays offer a powerful tool for accurately measuring cell lysis in therapeutic antibody development.

iLite CDC Reporter Gene Assays

Our iLite assays streamline the assessment of antibody-mediated CDC, a crucial mechanism in immune responses and a common mechanism of action (MoA) for therapeutic antibodies.

  • A true measure of cell lysis, ideal for screening mAbs with CDC MoA
  • Uses the brilliant Svar LUC reporter-gene system for enhanced stability and precise quantification of cell death
  • "Assay-ready" format for rapid and convenient use
  • Easily adapted to other targets such as HER2, EGFR, mTNF, mVEGF, or your target of choice

Our CDC Reporter-Gene Assays

BM5028

iLite® CD20 (+) Svar Luc Assay Ready Cells

Designed for sensitive and reproducible assessment of CDC activity

CELL-BASED
arrow
Cell-based reporter gene bioassay | CDC Bioassays | BM5028 | CDC | Complement | Cell-based reporter gene assay | Luminescence | Complement Products |

Didn't find what you were looking for?

We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.

Contact Us

iLite News

previous
Introducing the new iLite® C3a Assay Ready Cells

26 JANUARY 2026

Introducing the new iLite® C3a Assay Ready Cells

Read post
Improved Speed and Accuracy in Immunogenicity Testing

25 JANUARY 2026

Improved Speed and Accuracy in Immunogenicity Testing

Read post
Transitioning to Second-Generation iLite Cells

25 JANUARY 2026

Transitioning to Second-Generation iLite Cells

Read post
next
See more news >

iLite Downloads

previous
Mechanism-linked Potency Assays Drive Gene Therapy Success

26 JANUARY 2026

Mechanism-linked Potency Assays Drive Gene Therapy Success

Read post
Cell-based Assays in Immuno-oncology: Advancing Bispecific Antibody Development

25 JANUARY 2026

Cell-based Assays in Immuno-oncology: Advancing Bispecific Antibody Development

Read post
Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeutics

25 JANUARY 2026

Biosimilar Development: Experts Discuss Analytical Characterization Toolkits for Antibody Therapeuti...

Read post
next
See more downloads >

Contact our iLite team

Write us a message and a complement specialist will get in touch